Investing Strategies

March 22, 2019

Companies covered: Boeing Company (The) (NYSE:BA), Airbus SE (OTCMKTS:EADSY), Broadcom Ltd (NASDAQ:AVGO), Analog Devices, Inc. (NASDAQ:ADI), Royal Caribbean Cruises Ltd. (NYSE:RCL), Alphabet Inc (NASDAQ:GOOG), JPMorgan Chase & Co. (NYSE:JPM), Wells Fargo & Company (NYSE:WFC), Exxon Mobil Corporation (NYSE:XOM), Facebook, Inc. (NASDAQ:FB), Phillips 66 (NYSE:PSX), ConocoPhillips (NYSE:COP), Toronto Dominion Bank (The) (NYSE:TD), General Electric Company (NYSE:GE)

Buy ($175)

Proprietary Genome Editing Platforms

March 22, 2019

Companies covered: Celyad SA (ADR) (NASDAQ:CYAD), bluebird bio, Inc. (NASDAQ:BLUE), Spark Therapeutics, Inc. (NASDAQ:ONCE), Gilead Sciences, Inc. (NASDAQ:GILD), Novartis AG (NYSE:NVS), Rocket Pharmaceuticals (NASDAQ:RCKT), Biogen Inc. (NASDAQ:BIIB), Ionis Pharmaceuticals Inc (NASDAQ:IONS), BioMarin Pharmaceutical Inc. (NASDAQ:BMRN), Sangamo Therapeutics, Inc. (NASDAQ:SGMO), Pfizer, Inc. (NYSE:PFE), Abeona Therapeutics (NASDAQ:ABEO), LogicBio Therapeutics (NASDAQ:LOGC), Krystal Biotech (NASDAQ:KRYS), Global Blood Therapeutics (NASDAQ:GBT), Lonza Group AG (ADR) (OTCMKTS:LZAGY), Roche Holding Ltd. (ADR) (OTCMKTS:RHHBY), Celgene Corporation (NASDAQ:CELG), Bristol-Myers Squibb Company (NYSE:BMY), uniQure N.V. (NASDAQ:QURE), Sarepta Therapeutics, Inc. (NASDAQ:SRPT), CRISPR Therapeutics AG (NASDAQ:CRSP), Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX), Voyager Therapeutics (NASDAQ:VYGR), Lysogene SA (EPA:LYS), Nightstar Therapeutics PLC (NASDAQ:NITE), Denali Therapeutics (NASDAQ:DNLI), Arcturus Therapeutics Ltd. (NASDAQ:ARCT), NeuBase Therapeutics, Inc. (NASDAQ:NBSE), Bio-Path Holdings, Inc. (NASDAQ:BPTH)

Buy ($175)

Biotechnology and Pharmaceuticals

March 15, 2019

Companies covered: Gilead Sciences, Inc. (NASDAQ:GILD), CRISPR Therapeutics AG (NASDAQ:CRSP), Editas Medicine (NASDAQ:EDIT), bluebird bio, Inc. (NASDAQ:BLUE), ProQR Therapeutics N.V. (NASDAQ:PRQR), Intellia Therapeutics (NASDAQ:NTLA), Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT), Genfit SA (OTCMKTS:GNFTF), Viking Therapeutics (NASDAQ:VKTX), InflaRx NV (NASDAQ:IFRX), ChemoCentryx, Inc. (NASDAQ:CCXI), Madrigal Pharmaceuticals (NASDAQ:MDGL), Celgene Corporation (NASDAQ:CELG), VBI Vaccines Inc. (NASDAQ:VBIV), Acer Therapeutics (NASDAQ:ACER), SCYNEXIS, Inc. (NASDAQ:SCYX), Johnson & Johnson (NYSE:JNJ), Takeda Pharmaceutical Co. Ltd. (NYSE:TAK), Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), Proteon Therapeutics, Inc. (NASDAQ:PRTO), Cellectar Biosciences, Inc. (NASDAQ:CLRB), Chiasma (NASDAQ:CHMA), Veru (NASDAQ:VERU), Arcturus Therapeutics Ltd. (NASDAQ:ARCT), Medicenna Therapeutics Corp. (OTCMKTS:MDNAF), Catabasis Pharmaceuticals Inc (NASDAQ:CATB), Actinium Pharmaceuticals, Inc. (NYSEAMERICAN:ATNM), Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN), Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX), Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN), Wave Life Sciences Ltd (NASDAQ:WVE), Merck & Company, Inc. (NYSE:MRK), AbbVie Inc. (NYSE:ABBV), Sarepta Therapeutics, Inc. (NASDAQ:SRPT), Solid Biosciences (NASDAQ:SLDB), Pfizer, Inc. (NYSE:PFE), Biogen Inc. (NASDAQ:BIIB), Amgen Inc. (NASDAQ:AMGN), MacroGenics, Inc. (NASDAQ:MGNX), Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), Astrazeneca PLC (NYSE:AZN), Novartis AG (NYSE:NVS), Strongbridge Biopharma plc (NASDAQ:SBBP), Moderna (NASDAQ:MRNA), Spark Therapeutics, Inc. (NASDAQ:ONCE), Mustang Bio, Inc. (NASDAQ:MBIO), CEL-SCI Corporation (NYSEAMERICAN:CVM), Eli Lilly and Company (NYSE:LLY), vTv Therapeutics Inc (NASDAQ:VTVT), Titan Pharmaceuticals, Inc. (NASDAQ:TTNP), ProMIS Neurosciences (TSE:PMN), BioPorto A/S (CPH:BIOPOR), InMed Pharmaceuticals, Inc. (OTCMKTS:IMLFF), Protagonist Therapeutics, Inc. (NASDAQ:PTGX), Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP), True Leaf Medicine International Ltd. (OTCMKTS:TRLFF), Auris Medical Holding AG (NASDAQ:EARS), Cellectis S.A. (NASDAQ:CLLS), Celyad SA (ADR) (NASDAQ:CYAD), Adaptimmune Therapeutics plc (NASDAQ:ADAP), Mirati Therapeutics, Inc. (NASDAQ:MRTX), Infinity Pharmaceuticals, Inc. (NASDAQ:INFI), T2 Biosystems, Inc. (NASDAQ:TTOO), Nightstar Therapeutics PLC (NASDAQ:NITE), BioMarin Pharmaceutical Inc. (NASDAQ:BMRN), Blueprint Medicines Corp. (NASDAQ:BPMC), Genocea Biosciences, Inc. (NASDAQ:GNCA), Bristol-Myers Squibb Company (NYSE:BMY), Verastem, Inc. (NASDAQ:VSTM), Bayer AG (ADR) (OTCMKTS:BAYRY), Clovis Oncology, Inc. (NASDAQ:CLVS), Deciphera Pharmaceuticals (NASDAQ:DCPH), BerGenBio ASA (FRA:7BG), Forty Seven (NASDAQ:FTSV), Neon Therapeutics (NASDAQ:NTGN), Gritstone Oncology (NASDAQ:GRTS), OSE Immunotherapeutics SA (OTCMKTS:ORPOF), Roche Holding Ltd. (ADR) (OTCMKTS:RHHBY), Mesoblast Limited (NASDAQ:MESO)

Buy ($175)

Investing Strategies

March 15, 2019

Companies covered: Ringcentral, Inc. (NYSE:RNG), Cisco Systems, Inc. (NASDAQ:CSCO), AT&T Inc. (NYSE:T), SAP SE (NYSE:SAP), Everbridge (NASDAQ:EVBG), Chevron Corporation (NYSE:CVX), Microsoft Corporation (NASDAQ:MSFT), Tandem Diabetes Care, Inc. (NASDAQ:TNDM), Medtronic, Inc. (NYSE:MDT), Johnson & Johnson (NYSE:JNJ), DexCom, Inc. (NASDAQ:DXCM), Euronet Worldwide, Inc. (NASDAQ:EEFT), Netflix, Inc. (NASDAQ:NFLX), Visa Inc. (NYSE:V), Avaya Holdings Corp. (NYSE:AVYA), Broadcom Ltd (NASDAQ:AVGO), Xilinx, Inc. (NASDAQ:XLNX), Skyworks Solutions, Inc. (NASDAQ:SWKS), Synchrony Financial (NYSE:SYF), General Electric Company (NYSE:GE), Amazon.com, Inc. (NASDAQ:AMZN), Paypal Holdings Inc (NASDAQ:PYPL), Wal-Mart Stores, Inc. (NYSE:WMT), Marathon Petroleum Corporation (NYSE:MPC), MPLX LP (NYSE:MPLX), Merck & Company, Inc. (NYSE:MRK), Becton, Dickinson and Company (NYSE:BDX), CVS Health Corporation (NYSE:CVS), Monolithic Power Systems, Inc. (NASDAQ:MPWR), Red Rock Resorts Inc (NASDAQ:RRR), New Relic, Inc. (NYSE:NEWR), Tactile Systems Technology, Inc. (NASDAQ:TCMD), Blue Bird Corp. (NASDAQ:BLBD), Ford Motor Company (NYSE:F), Cummins Inc. (NYSE:CMI), Home BancShares, Inc. (NASDAQ:HOMB), Prestige Consumer Healthcare (NYSE:PBH), The Hain Celestial Group, Inc. (NASDAQ:HAIN), Pepsico, Inc. (NYSE:PEP), Campbell Soup Company (NYSE:CPB), Dine Brands Global (NYSE:DIN), Choice Hotels International, Inc. (NYSE:CHH), HealthEquity, Inc. (NASDAQ:HQY), Box, Inc. (NYSE:BOX), Alphabet Inc (NASDAQ:GOOG), The Ultimate Software Group, Inc. (NASDAQ:ULTI), Apple Inc. (NASDAQ:AAPL), Boeing Company (The) (NYSE:BA), Hexcel Corporation (NYSE:HXL), Airbus SE (OTCMKTS:EADSY), Dropbox (NASDAQ:DBX)

Buy ($175)

Investing Strategies

March 01, 2019

Companies covered: SVB Financial Group (NASDAQ:SIVB), Aalberts Industries N.V. (AMS:AALB), Partners Group Holding (SWX:PGHN), Salesforce.com Inc (NYSE:CRM), Darling Ingredients Inc. (NYSE:DAR), Timken Company (The) (NYSE:TKR), Brink's Company (The) (NYSE:BCO), Clean Harbors, Inc. (NYSE:CLH), Amazon.com, Inc. (NASDAQ:AMZN), Facebook, Inc. (NASDAQ:FB), BB&T Corporation (NYSE:BBT), SunTrust Banks, Inc. (NYSE:STI), JPMorgan Chase & Co. (NYSE:JPM), Bank of America Corporation (NYSE:BAC), Goldman Sachs Group, Inc. (The) (NYSE:GS), MetLife, Inc. (NYSE:MET), BorgWarner Inc. (NYSE:BWA), PNC Financial Services Group, Inc. (The) (NYSE:PNC)

Buy ($175)

Latest News